Abstract：Objective :To investigate the correlation of cyclosporin A (CsA)blood concentrations with acute graft-versushost-disease(aGVHD) and its adverse reaction(ADR) in children undergoing hematopoietic stem cell transplantation. Methods :Chemiluminescent immunoassay was applied to determining peak and trough concentrations of CsA in whole blood, while the incidence of aGVHD as well as liver and renal functions were monitored. Based on the results, the correlation of peak or trough concentrations of CsA with aGVHD and ADR are discussed. Results :when the CsA trough concentration (C0) reached 360μg?L–1 and the peak concentration was >1500μg?L–1, alanine aminotransferase (ALT) and aspartate amino transferase(AST) increased gradually, the children’s hepatic function become abnormal. However, as the decrease of peak and trough concentration, ALT and AST also fall off, and the patient does not develop aGVHD. Conclusion :There is a correlation between both peak and trough concentrations of CsA in whole blood with aGVHD or ADR, but it is unclear which one is more significant, more samples were n eeded to confirm it.
王翔岩，钟旭丽，宋泽亮，宋远，师晓东. 儿童造血干细胞移植后环孢素A 血药浓度监测[J]. 临床药物治疗杂志, 2015, 13(6): 21-24.
WANG Xiang-yan, ZHONG Xu-li, SONG Ze-liang, SONG Yuan, SHI Xiao-dong. Therapeutic drug monitoring of cyclosporine A in children undergoing hematopoietic stem cell transplantation. CLINICAL MEDICATION JOURNAL, 2015, 13(6): 21-24.
[1] Jacobsohn D A. Acute graft-versus-host disease in children.[J]. Bone Marrow Transplant, 2008, 41(2):215-221.
[2] Jorga A, Holt D W, Johnston A. Therapeutic drug monitoring of cyclosporine.[J]. Transplant Proc, 2004, 36(2):396S-403S.
[3] Willemze A J, Cremers S C, Schoemaker R C, et al. Ciclosporin kinetics in children after stem cell transplantation[J]. Br J ClinPharmacol, 2008, 66(4):539-545.
[4] 朱愿超，梁良，赵明，等. 再生障碍性贫血患者环孢素A 血药浓度监测的回顾性分析[J]. 临床药物治疗杂志, 2015, 13(5):20-24
[5] Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine Transplant.[J]. Proc, 2004,36(2):420S-425S
[6] Jaiswal J, Gupta S K, Dash S C,.et al. Neoral monitoring by limited sampling area under the concentration time curve in stable Indian renal transplant recipients.[J]. Transplant Proc, 2003, 35(4):1298-1299.
[7] Wang C H, Ko W J, Chou N K, et al. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients[J].Transplant Proc, 2004,36(8):2390-2392.
[8] Schrauder A,Saleh S, Sykora K W, et al. Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The though level is not enough[J]. Pediatric Transplantation, 2009, 13(4):444-450
[9] Punnett A, Sung L, Price V, et al. Achievement of target cyclosporine concentrations as a predictor of severe acute GvHD in children receiving cyclosporine and methotrexate prophylaxis[J]. Ther Drug Monit, 2007, 29(6):750-757.
[10] Martin P, Bleyzac N, Souillet G, et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors[J]. Bone Marrow Transplant, 2003, 32(9):881-887.
[11] Kanda Y, Hyo R, Yamashita T, et al. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor[J]. Am J Hematol, 2006, 81(11): 838-844.
[12] Ram R, Storer B, Mielcarek M, et al. Association between calcineurin inhibitor blood concentration and outcomes after allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant,2012, 18(3): 414-422.
[13] Malard F, Szydlo R, Brissot E, et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-hostdisease after allogeneic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2010, 16(1):28-34.
[14] Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT).Chronic Leukaemia Working Party of the EBMT[J]. Bone Marrow Transplant, 1997, 19(8):759-764.
[15] 范芳，谢瑞祥，吴国森. 改良反相高效液相色谱法测定非清髓性异基因干细胞移植患者全血中环孢素A 的C2 浓度[J]. 中国医院药学杂志, 2004, 24(5):282-283
[16] Oellerich M, Armstrong V W, Streit F, et al. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients[J].Clini Biochemist, 2004, 37(6):424-428.
[17] Schrauder A, Saleh S, Sykora K W, et al. Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients.The trough level is not enough[J].Pediatr Transplant, 2009,13(4):444-450.
[18] Sullivan K M.Graft-versus-host disease. In: Thomas ED.Hemalopoietic cell transplantation[M]. 2nd ed. Malden: Blackwell Science Inc, 1999:515-536.
[19] 王羽，裴云萍，方芸. 造血干细胞移植中环孢素血药浓度与其不良反应的相关性研究[J]. 药学服务与研究, 2008, 8(1):21-23
[20] 贾暖，孙成春，董玉波. 骨髓移植患者术后环孢素血药浓度监测[J]. 中国医院用药评价与分析, 2002, 12(5):436-437
[21]Wilhelm A J, de Graaf P, Veldkamp A I, et al. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy[J].Br J Clin Pharmacol, 2012, 73(4):553-563
[22] Dupuis L L, Seto W, Teuffel O,et al.Prediction of Area under the cyclosporine Concentration Versus Time Curve in Children Undergoing Hematopoietic Stem Cell Transplantation[J].Biol Blood Marrow Transplant, 2013, 19(3):418-423.
2015, Vol. 13 
